• Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy
Friday, May 9, 2025
Daily The Business
  • Login
No Result
View All Result
DTB
No Result
View All Result
DTB

Ferozsons Laboratories’ subsidiary BF Biosciences launches human insulin

August 15, 2024
in Business & Finance
Ferozsons Laboratories’ subsidiary BF Biosciences launches human insulin
Share on FacebookShare on TwitterWhatsapp

Pakistan’s pharmaceutical company BF Biosciences Limited (BFBL) has successfully launched a human insulin under the brand name ‘Ferulin’.

The development was shared by Ferozsons Laboratories Limited, the parent company of BFBL, in a notice to the Pakistan Stock Exchange (PSX) on Thursday.

“We are pleased to inform you that BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited, has successfully launched human insulin under the brand name ‘Ferulin’,” read the notice.

It is pertinent to inform that human insulin is a synthetic form of insulin that is identical to the insulin produced naturally by the human pancreas. Insulin is a hormone that plays a crucial role in managing blood glucose levels, especially for people with diabetes.

Meanwhile, the company in its statement said the launch marks a significant milestone in its commitment to stop diabetes, expand the product portfolio and enhance the availability of life-saving medicines in the market.

“Ferulin has been developed with the highest quality standards and is intended to provide effective and affordable diabetes treatment to patients across Pakistan,” the company claimed.

“We are confident that Ferulin will positively impact our subsidiary’s growth and will further strengthen our mission to address unmet patient needs,” it added.

BFBL, a joint venture between Ferozsons Laboratories Limited and Argentina’s Bagó Group, specialises in the import, manufacturing, marketing, and distribution of pharmaceutical products.

The company is planning an initial public offering (IPO) at the PSX, aiming to raise at least Rs1.375 billion ($4.94 million) by issuing 25 million shares at a floor price of Rs55 per share.

The company is a pioneer in local manufacturing of hepatitis related medicines (i.e. interferon injections).

In 2020, BFBL executed a non-exclusive license agreement with Gilead Sciences, Inc. for the manufacture and sale of Remdesivir (an anti-viral drug for the treatment of COVID-19 patients) under Gilead’s Global Patient Solutions (GPS) Program.

BFBL successfully produced Remdesivir during the COVID-19 pandemic, contributing approximately Rs2 billion to its topline in FY2021-FY2022.

Tags: BF Biosciences LimitedDiabetesFerozsons Laboratories LimitedFerulinhuman insulinPAKISTAN HEALTH SECTORPakistan pharma sectorPharma sectorpharmaceutical companiesPharmaceutical IndustryPharmaceutical productsPSX notice
Share15Tweet10Send
Previous Post

Columbia’s president resigns after months of turmoil punctuated by clashes over Israel-Hamas war

Next Post

Nearly 4,000 Pakistan companies join Dubai Chamber of Commerce in six months

Related Posts

Indian rupee’s rally to stall by end of July, weaker times ahead
Business & Finance

Indian rupee’s rally to stall by end of July, weaker times ahead

May 7, 2025
KIBOR falls after SBP cut policy rate
Business & Finance

KIBOR falls after SBP cut policy rate

May 7, 2025
India’s Bank of Baroda expects margin pressure to persist for two more quarters
Business & Finance

India’s Bank of Baroda expects margin pressure to persist for two more quarters

May 6, 2025
SBP revises O/N repo, reverse repo rates
Business & Finance

SBP revises O/N repo, reverse repo rates

May 6, 2025
ADB to scale up food security support to $40bn by 2030
Business & Finance

ADB to scale up food security support to $40bn by 2030

May 4, 2025
Saudi chemicals group SABIC reports Q1 net loss of $323 million
Business & Finance

Saudi chemicals group SABIC reports Q1 net loss of $323 million

May 5, 2025

Popular Post

  • FRSHAR Mail

    FRSHAR Mail set to redefine secure communication, data privacy

    126 shares
    Share 50 Tweet 32
  • How to avoid buyer’s remorse when raising venture capital

    33 shares
    Share 337 Tweet 211
  • Microsoft to pay off cloud industry group to end EU antitrust complaint

    45 shares
    Share 18 Tweet 11
  • Saudi Arabia Launches World’s First Self-Driving Flying Taxi to Transport Hajj Pilgrims

    42 shares
    Share 17 Tweet 11
  • SingTel annual profit more than halves on $2.3bn impairment charge

    42 shares
    Share 17 Tweet 11
American Dollar Exchange Rate
  • Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy
Write us: info@dailythebusiness.com

© 2021 Daily The Business

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Need Help? Chat with us
Start a Conversation
Hi! Click one of our member below to chat on WhatsApp
The team typically replies in a few minutes.
DTB
No Result
View All Result
  • Advertise
  • Contact Us
  • Daily The Business
  • Privacy Policy

© 2021 Daily The Business

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.